{
    "id": 53,
    "fullName": "PIK3CA H1047R",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA H1047R is a hotspot mutation that lies within the kinase domain of the Pik3ca protein (UniProt.org). H1047R results in increased phosphorylation of Akt and Mek1/2, growth factor-independent cell survival, and transformation in cell culture (PMID: 26627007, PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "H1047R",
    "createDate": "01/17/2014",
    "updateDate": "02/07/2020",
    "referenceTranscriptCoordinates": {
        "id": 171861,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179234297A>G",
        "cDna": "c.3140A>G",
        "protein": "p.H1047R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 966,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 967,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1178,
                "therapyName": "Bevacizumab + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 970,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13080,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 972,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1419,
                "therapyName": "Buparlisib + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 969,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 971,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1418,
                "therapyName": "Buparlisib + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 968,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",
            "molecularProfile": {
                "id": 1575,
                "profileName": "ERBB2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1417,
                "therapyName": "Buparlisib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 240,
                    "pubMedId": 23940356,
                    "title": "Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1801,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-04691502 inhibited Pi3k signaling, resulted in growth inhibition of ovarian cancer cells harboring PIK3CA H1047R in culture and in cell line xenograft models (PMID: 21750219).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 865,
                "therapyName": "PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 226,
                    "pubMedId": 21750219,
                    "title": "PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21750219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8222,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of an anaplastic thyroid cancer cell line harboring PIK3CA H1047R in culture (PMID: 21289267).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 4664,
                "therapyName": "MK2206 + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6573,
                    "pubMedId": 21289267,
                    "title": "The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21289267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11515,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line xenograft model harboring PIK3CA H1047R demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9597,
                    "pubMedId": 28539475,
                    "title": "The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539475"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4230,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1288,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1016,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirolimus (rapamycin) failed to inhibit tumor growth in a mouse lung adenocarcinoma model expressing the PIK3CA H1047R mutation (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5866,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis of head and neck squamous carcinoma cells harboring PIK3CA H1047R (PMID: 26589432).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 3967,
                "therapyName": "Radiotherapy + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4223,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7452,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited tumor growth in a patient-derived xenograft (PDX) model of bladder cancer harboring PIK3CA H1047R (PMID: 26270481).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6363,
                    "pubMedId": 26270481,
                    "title": "Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26270481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R treated with SHR-A1307 demonstrated inhibition of cell growth in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1289,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10289,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer xenograft model harboring PIK3CA H1047R was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth (PMID: 27186432).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1037,
                "therapyName": "M2698",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7643,
                    "pubMedId": 27186432,
                    "title": "M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27186432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12502,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) inhibited Akt phosphorylation and tumor growth, prolonged survival in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA H1047R (PMID: 28808038).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9961,
                    "pubMedId": 28808038,
                    "title": "The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28808038"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4251,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20952,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Buparlisib (BKM120) and Selumetinib (AZD6244) led to a synergistic effect, resulting in growth inhibition of astrocytoma cells expressing PIK3CA H1047R, but did not result in an effect as high as that seen in cells expressing PIK3CA R88Q or PIK3CA E542K in culture (PMID: 29975751).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 4652,
                "therapyName": "Buparlisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18213,
                    "pubMedId": 29975751,
                    "title": "PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29975751"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19933,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, borussertib inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R in culture (PMID: 30858154).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 9256,
                "therapyName": "Borussertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17595,
                    "pubMedId": 30858154,
                    "title": "Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30858154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4258,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4263,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2794,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5363 inhibited growth in a patient-derived xenograft model of gastric cancer harboring a PIK3CA H1047R mutation (PMID: 24088382).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1081,
                    "pubMedId": 24088382,
                    "title": "The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24088382"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with Miransertib (ARQ092) in culture, resulting in inhibition of cell proliferation (PMID: 26469692).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11723,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing PIK3CA H1047R were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 2000,
                "therapyName": "Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9728,
                    "pubMedId": 28424201,
                    "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3760,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12531,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of or sequential treatment with Pictilisib (GDC-0941) and Platinol (cisplatin) significantly delayed tumor growth and prolonged survival in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA H1047R (PMID: 28808038).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1554,
                "therapyName": "Cisplatin + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9961,
                    "pubMedId": 28808038,
                    "title": "The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28808038"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9357,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human colorectal cancer cell line xenograft tumors harboring PIK3CA H1047R (PMID: 23986086).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1086,
                    "pubMedId": 23986086,
                    "title": "Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23986086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18083,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, combination of Afinitor (everolimus) and hormone therapy resulted in improved median progression-free survival (8.8 vs 4.1 months, p=0.02) in patients with hormone receptor-positive metastatic breast cancer harboring PIK3CA H1047R (n=6) compared to patients without PIK3CA H1047R (n=10) (PMID: 31088410).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15992,
                    "pubMedId": 31088410,
                    "title": "Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31088410"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15872,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Buparlisib (BKM120) in combination with Taxol (paclitaxel) resulted in a durable partial response in a patient with breast metaplastic carcinoma harboring PIK3CA H1047R, with a total response period of 70 weeks and an overall survival of 42 months (PMID: 30577988).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4680,
                "name": "breast metaplastic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13879,
                    "pubMedId": 30577988,
                    "title": "PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30577988"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6003,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PIK3CA H1047R were sensitive to Rapamune (sirolimus), resulting in inhibition of transformation in culture (PMID: 15647370).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1077,
                    "pubMedId": 15647370,
                    "title": "Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15647370"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7533,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A66 delayed tumor growth in an ovarian cancer cell line xenograft model harboring PIK3CA H1047R (PMID: 21668414).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 617,
                "therapyName": "A66",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 223,
                    "pubMedId": 21668414,
                    "title": "A drug targeting only p110\u03b1 can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21668414"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4237,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10268,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ 751 in culture, resulting in inhibition of cell proliferation (PMID: 26469692).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 4331,
                "therapyName": "ARQ 751",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18084,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, combination of Afinitor (everolimus) and hormone therapy resulted in improved median progression-free survival (8.8 vs 4.1 months, p=0.02) in patients with hormone receptor-positive metastatic breast cancer harboring PIK3CA H1047R (n=6) compared to patients without PIK3CA H1047R (n=10) (PMID: 31088410).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15992,
                    "pubMedId": 31088410,
                    "title": "Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31088410"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3127,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3636,
                    "pubMedId": 17314276,
                    "title": "Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17314276"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8814,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R in culture, and inhibited AKT signaling and tumor growth in a PIK3CA H1047R-mutant cell line xenograft model (PMID: 27699769).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8214,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring PIK3CA H1047R (PMID: 21289267).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6573,
                    "pubMedId": 21289267,
                    "title": "The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21289267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11445,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, four patients with breast cancer harboring PIK3CA H1047R demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9393,
                    "pubMedId": 28331003,
                    "title": "Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28331003"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3752,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 inhibited tumor growth in mouse xenografts of ovarian cancer with a Pik3ca H1047R mutation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2830).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 2013,
                "therapyName": "AZD8835",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4105,
                    "pubMedId": null,
                    "title": "Discovery of AZD8835, a potent and selective inhibitor of PI3K? and PI3K? for the treatment of PIK3CA-dependent cancers",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2830.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18935,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R in culture, inhibited tumor progression in a transgenic mouse model, and induced cell cycle arrest, and inhibited PI3K signaling and tumor growth in cell line xenograft models (PMID: 30003928).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 8687,
                "therapyName": "CYH33",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16074,
                    "pubMedId": 30003928,
                    "title": "Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K\u03b1-selective inhibitor CYH33 in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30003928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7972,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6528,
                    "pubMedId": 26013318,
                    "title": "Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26013318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8556,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rigosertib (ON 01910.Na) inhibited oncogenic transformation in fibroblast cells over-expressing Pik3ca H1047R in culture (PMID: 27104980).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6686,
                    "pubMedId": 27104980,
                    "title": "A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27104980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2776,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A66 delayed tumor growth in human tumor xenograft models harboring PIK3CA H1047R mutations (PMID: 21668414).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 617,
                "therapyName": "A66",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 223,
                    "pubMedId": 21668414,
                    "title": "A drug targeting only p110\u03b1 can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21668414"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19315,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), Afinitor (everolimus) demonstrated comparable progression-free survival benefit in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring wild-type (HR=0.43) or mutant (HR=0.37) PIK3CA, similar benefit was observed in subgroups harboring PIK3CA H1047R (HR=0.37) and PIK3CA E545K/E542K (HR=0.30) (PMID: 28183140; NCT00863655).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10362,
                    "pubMedId": 28183140,
                    "title": "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1015,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 promoted tumor regression in a mouse lung adenocarcinoma model expressing PIK3CA H1047R (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10358,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DHM25 increased cell death in breast cancer cell lines harboring PIK3CA H1047R in culture (PMID: 26237138).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 5494,
                "therapyName": "DHM25",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8367,
                    "pubMedId": 26237138,
                    "title": "A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26237138"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R were resistant to Erbitux (cetuximab) in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7969,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6528,
                    "pubMedId": 26013318,
                    "title": "Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26013318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4244,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2837,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CH5132799 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with ovarian cancer harboring PIK3CA H1047R (PMID: 25231405).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3498,
                    "pubMedId": 25231405,
                    "title": "First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25231405"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17325,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, none of the 4 patients harboring PIK3CA H1047R demonstrated response (PMID: 31158500; NCT02785913).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15376,
                    "pubMedId": 31158500,
                    "title": "SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158500"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4688,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring PIK3CA H1047R in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 3596,
                "therapyName": "Sirolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4668,
                    "pubMedId": 26882569,
                    "title": "A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26882569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9356,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) inhibited cell proliferation of a dietary restriction-resistant PIK3CA H1047R-harboring human breast cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23986086).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1086,
                    "pubMedId": 23986086,
                    "title": "Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23986086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines harboring PIK3CA H1047R demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) in culture (PMID: 25977343).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6585,
                    "pubMedId": 25977343,
                    "title": "MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25977343"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18390,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Piqray (Alpelisib) decreased Akt phosphorylation and inhibited PI3K signaling, and demonstrated dose-dependent inhibition of survival in human pluripotent stem cells harboring PIK3CA H1047R in culture (PMID: 30948643).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16164,
                    "pubMedId": 30948643,
                    "title": "Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30948643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2946,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21558396).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7973,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6528,
                    "pubMedId": 26013318,
                    "title": "Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26013318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1822,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC amplification led to BEZ235 resistance in PIK3CA H1074R expressing human breast tumor cells in culture (PMID: 21876152).",
            "molecularProfile": {
                "id": 3606,
                "profileName": "MYC amp PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2233,
                    "pubMedId": 21876152,
                    "title": "PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21876152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10276,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring PIK3CA P539R and PH1047R was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 9797,
                "profileName": "PIK3CA P539R PIK3CA H1047R"
            },
            "therapy": {
                "id": 4331,
                "therapyName": "ARQ 751",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-04691502 inhibited Akt phosphorylation and proliferation of breast cancer cells harboring both PIK3CA P539R and H1047R in culture (PMID: 21750219).",
            "molecularProfile": {
                "id": 9797,
                "profileName": "PIK3CA P539R PIK3CA H1047R"
            },
            "therapy": {
                "id": 865,
                "therapyName": "PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 226,
                    "pubMedId": 21750219,
                    "title": "PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21750219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10273,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells harboring PIK3CA P539R and H1047R were sensitive to Miransertib (ARQ092) in culture, demonstrating inhibition of cell growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 9797,
                "profileName": "PIK3CA P539R PIK3CA H1047R"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2876,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 693,
                "therapyName": "CC-223",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 3513,
                    "pubMedId": 25855786,
                    "title": "CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25855786"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4942,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3010,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 843,
                    "pubMedId": 20570890,
                    "title": "Genomic and biological characterization of exon 4 KRAS mutations in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20570890"
                },
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3131,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4947,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12024,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9976,
                    "pubMedId": 27602501,
                    "title": "Specific inhibition of p110\u03b1 subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27602501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2856,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 3025,
                "therapyName": "Gedatolisib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2836,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3903,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 3398,
                "therapyName": "Camptothecin + Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3902,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 1074,
                "therapyName": "Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 4272,
                    "pubMedId": 16707468,
                    "title": "KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16707468"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2859,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 2447,
                "therapyName": "AT-7867",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 2290,
                    "pubMedId": 20423992,
                    "title": "AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20423992"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3901,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 3396,
                "therapyName": "Gedatolisib + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3639,
                    "pubMedId": 24042735,
                    "title": "Epigenetic and genetic features of 24 colon cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24042735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3125,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",
            "molecularProfile": {
                "id": 10752,
                "profileName": "ERBB2 amp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3636,
                    "pubMedId": 17314276,
                    "title": "Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17314276"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2970,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",
            "molecularProfile": {
                "id": 10752,
                "profileName": "ERBB2 amp PIK3CA H1047R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2968,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",
            "molecularProfile": {
                "id": 10752,
                "profileName": "ERBB2 amp PIK3CA H1047R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2975,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).",
            "molecularProfile": {
                "id": 10752,
                "profileName": "ERBB2 amp PIK3CA H1047R"
            },
            "therapy": {
                "id": 3039,
                "therapyName": "CH5132799 + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18940,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R and ERBB2 (HER2) amplification in culture (PMID: 30003928).",
            "molecularProfile": {
                "id": 10752,
                "profileName": "ERBB2 amp PIK3CA H1047R"
            },
            "therapy": {
                "id": 8687,
                "therapyName": "CYH33",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16074,
                    "pubMedId": 30003928,
                    "title": "Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K\u03b1-selective inhibitor CYH33 in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30003928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4573,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 3548,
                "therapyName": "Buparlisib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4571,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4572,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9692,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, 80% (4/5) of estrogen-receptor positive breast cancer patients harboring PIK3CA H1047R demonstrated a clinical response, including either partial response or stable disease, when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 20269,
                "profileName": "ESR1 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17134,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 20269,
                "profileName": "ESR1 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8368,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Faslodex (fulvestrant) and Pictilisib (GDC-0941) resulted in tumor regression in estrogen-receptor (ER) positive breast cancer cell line xenograft models harboring PIK3CA H1047R (PMID: 26733612).",
            "molecularProfile": {
                "id": 20269,
                "profileName": "ESR1 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 4357,
                "therapyName": "Fulvestrant + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6631,
                    "pubMedId": 26733612,
                    "title": "Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5622,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).",
            "molecularProfile": {
                "id": 21303,
                "profileName": "KRAS wild-type PIK3CA H1047R"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7082,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24398,
                "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7457,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",
            "molecularProfile": {
                "id": 25513,
                "profileName": "ERBB2 over exp PIK3CA H1047R SRC over exp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6363,
                    "pubMedId": 26270481,
                    "title": "Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26270481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7456,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",
            "molecularProfile": {
                "id": 25513,
                "profileName": "ERBB2 over exp PIK3CA H1047R SRC over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6363,
                    "pubMedId": 26270481,
                    "title": "Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26270481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17747,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 25951,
                "profileName": "ERBB2 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7748,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",
            "molecularProfile": {
                "id": 25951,
                "profileName": "ERBB2 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7806,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, upregulation of Akt3 expression was detected in breast cancer cells harboring PIK3CA H1047R that acquired resistance to Ipatasertib (GDC-0068) in culture (PMID: 27297869).",
            "molecularProfile": {
                "id": 26047,
                "profileName": "AKT3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6502,
                    "pubMedId": 27297869,
                    "title": "Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297869"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7805,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, upregulation of Akt3 expression was detected in breast cancer cells harboring PIK3CA H1047R that acquired resistance to MK2206 in culture (PMID: 27297869).",
            "molecularProfile": {
                "id": 26047,
                "profileName": "AKT3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6502,
                    "pubMedId": 27297869,
                    "title": "Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297869"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8121,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Odomzo (sonidegib) inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing Pik3ca H1047R in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26168,
                "profileName": "PIK3CA H1047R PTCH1 inact mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10815,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10812,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 5650,
                "therapyName": "Dabrafenib + Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10814,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8567,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 26360,
                "profileName": "KRAS G13D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8568,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",
            "molecularProfile": {
                "id": 26361,
                "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8577,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26366,
                "profileName": "KRAS G12C PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8582,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer cell line expressing PIK3CA H1047R and over expressing MYC demonstrated resistance to Pictilisib (GDC-0941) in culture, and Pictilisib (GDC-0941) had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in increased tumor cell death and tumor shrinkage in mouse breast cancer cell line allograft models expressing PIK3CA H1047R and over expressing MYC and demonstrated increased efficacy over either agent alone (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 4774,
                "therapyName": "MS417 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8584,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with JQ1 reduced Myc levels, but did not inhibit growth of a mouse breast cancer cell line expressing PIK3CA H1047R and over expressing MYC in culture (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8590,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with MS417 did not inhibit growth of a mouse breast cancer cell line expressing PIK3CA H1047R and over expressing MYC in culture, and had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 3335,
                "therapyName": "MS417",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8697,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8695,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8596,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8702,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8703,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8601,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).",
            "molecularProfile": {
                "id": 26449,
                "profileName": "PIK3CA H1047R PTEN E307K"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8872,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fgf3 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26472,
                "profileName": "FGF3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gpr161 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26475,
                "profileName": "GPR161 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8875,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tbc1d3g over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26480,
                "profileName": "PIK3CA H1047R TBC1D3G over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ccnd1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26481,
                "profileName": "CCND1 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Srp54 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26484,
                "profileName": "PIK3CA H1047R SRP54 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Plekhf1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26487,
                "profileName": "PIK3CA H1047R PLEKHF1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crb3 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26490,
                "profileName": "CRB3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8914,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Ipatasertib (GDC-0068) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 restored Alpelisib (BYL719) sensitivity in breast cancer cells harboring PIK3CA H1047R and over expressing Pim1 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 4851,
                "therapyName": "Alpelisib + AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Afinitor (everolimus) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8913,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to MK2206 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8909,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Taselisib (GDC-0032) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8918,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to WYE-354 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2243,
                "therapyName": "WYE-354",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Torkinib (PP242) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8924,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGH447 restored Alpelisib (BYL719) sensitivity in breast cancer cells harboring PIK3CA H1047R and over expressing Pim1 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2419,
                "therapyName": "Alpelisib + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8915,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Rapamune (sirolimus) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26496,
                "profileName": "AKT1 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Akt2 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26507,
                "profileName": "AKT2 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pdpk1 (Pdk1) over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26511,
                "profileName": "PDPK1 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8884,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Samd4b over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26514,
                "profileName": "PIK3CA H1047R SAMD4B over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nudt3 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26518,
                "profileName": "NUDT3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8886,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Usp38 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26522,
                "profileName": "PIK3CA H1047R USP38 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8888,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mfsd5 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26524,
                "profileName": "MFSD5 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R and PTEN E307K resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26530,
                "profileName": "PIK3CA H1047R PIM1 over exp PTEN E307K"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim2 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26535,
                "profileName": "PIK3CA H1047R PIM2 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim3 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26536,
                "profileName": "PIK3CA H1047R PIM3 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8928,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGH447 sensitized breast cancer cells harboring PIK3CA H1047R, PIK3CA P539R, and with elevated Pim1 protein levels to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26539,
                "profileName": "PIK3CA P539R PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2419,
                "therapyName": "Alpelisib + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8975,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BKM120 inhibited tumor growth in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer harboring PIK3CA H1047R and expressing the short isoform of MST1R (RON) (PMID: 26289070).",
            "molecularProfile": {
                "id": 26623,
                "profileName": "MST1R pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6831,
                    "pubMedId": 26289070,
                    "title": "Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26289070"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8977,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BKM120 and BMS-777607 (ASLAN002) inhibited tumor growth in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer harboring PIK3CA H1047R and expressing the short isoform of MST1R (RON) (PMID: 26289070).",
            "molecularProfile": {
                "id": 26623,
                "profileName": "MST1R pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 4856,
                "therapyName": "BMS-777607 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6831,
                    "pubMedId": 26289070,
                    "title": "Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26289070"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8976,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-777607 (ASLAN002) inhibited tumor growth in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer harboring PIK3CA H1047R and expressing the short isoform of MST1R (RON) (PMID: 26289070).",
            "molecularProfile": {
                "id": 26623,
                "profileName": "MST1R pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 687,
                "therapyName": "BMS-777607",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6831,
                    "pubMedId": 26289070,
                    "title": "Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26289070"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9373,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9374,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9375,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10091,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",
            "molecularProfile": {
                "id": 27242,
                "profileName": "PIK3CA H1047R PTEN loss"
            },
            "therapy": {
                "id": 5381,
                "therapyName": "ABT-737 + BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10082,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).",
            "molecularProfile": {
                "id": 27242,
                "profileName": "PIK3CA H1047R PTEN loss"
            },
            "therapy": {
                "id": 5376,
                "therapyName": "BEZ235 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10097,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",
            "molecularProfile": {
                "id": 27242,
                "profileName": "PIK3CA H1047R PTEN loss"
            },
            "therapy": {
                "id": 5388,
                "therapyName": "ABT-737 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10085,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).",
            "molecularProfile": {
                "id": 27242,
                "profileName": "PIK3CA H1047R PTEN loss"
            },
            "therapy": {
                "id": 5377,
                "therapyName": "BEZ235 + WEHI-539",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN loss in culture (PMID: 30003928).",
            "molecularProfile": {
                "id": 27242,
                "profileName": "PIK3CA H1047R PTEN loss"
            },
            "therapy": {
                "id": 8687,
                "therapyName": "CYH33",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16074,
                    "pubMedId": 30003928,
                    "title": "Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K\u03b1-selective inhibitor CYH33 in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30003928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10545,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).",
            "molecularProfile": {
                "id": 27594,
                "profileName": "PIK3CA H1047R TP53 S90fs"
            },
            "therapy": {
                "id": 722,
                "therapyName": "DS-7423",
                "synonyms": null
            },
            "indication": {
                "id": 5304,
                "name": "ovarian clear cell adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4912,
                    "pubMedId": 24504419,
                    "title": "Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24504419"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10884,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12F and PIK3CA H1047R (PMID: 26855149).",
            "molecularProfile": {
                "id": 27820,
                "profileName": "KRAS G12F PIK3CA H1047R"
            },
            "therapy": {
                "id": 5671,
                "therapyName": "Dasatinib + Demcizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11518,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases demonstrated resistance to treatment with Buparlisib (BKM120) (PMID: 28539475).",
            "molecularProfile": {
                "id": 28117,
                "profileName": "ERBB3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9597,
                    "pubMedId": 28539475,
                    "title": "The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539475"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11524,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases was sensitive to the combined treatment of Buparlisib (BKM120) and Perjeta (pertuzumab), demonstrating delayed tumor growth and better survival when compared to either treatment alone (PMID: 28539475).",
            "molecularProfile": {
                "id": 28117,
                "profileName": "ERBB3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 6010,
                "therapyName": "Buparlisib + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9597,
                    "pubMedId": 28539475,
                    "title": "The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539475"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11523,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases was sensitive to the combined treatment of Buparlisib (BKM120) and LJM716, demonstrating delayed tumor growth and better survival when compared to either treatment alone (PMID: 28539475).",
            "molecularProfile": {
                "id": 28117,
                "profileName": "ERBB3 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 6009,
                "therapyName": "Buparlisib + LJM716",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9597,
                    "pubMedId": 28539475,
                    "title": "The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539475"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16744,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ER/PR positive, ERBB2 (HER2) negative breast cancer harboring ERBB2 (HER2) G776V, PIK3CA H1047R, and two MAP3K1 frameshift mutations demonstrated a positive clinical response for 13 months when treated with a combination of Herceptin (trastuzumab), Perjeta (pertuzumab) and Aromasin (exemestane) (Chudnovsky,Y et al. JCO Prec Onc, Aug 2017).",
            "molecularProfile": {
                "id": 31777,
                "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 8162,
                "therapyName": "Exemestane + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14794,
                    "pubMedId": null,
                    "title": "Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2\u2013Targeted Therapy",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.16.00037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16745,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an ER/PR positive, ERBB2 (HER2) negative breast cancer patient harboring ERBB2 (HER2) G776V, PIK3CA H1047R, and two MAP3K1 frameshift mutations who progressed while being treated with Herceptin (trastuzumab), Perjeta (pertuzumab), and Aromasin (exemestane) demonstrated a clinical response for nearly six months when switched to Herceptin (trastuzumab), Perjeta (pertuzumab), and Abraxane (nab-paclitaxel) (Chudnovsky,Y et al. JCO Prec Onc, Aug 2017).",
            "molecularProfile": {
                "id": 31777,
                "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 8163,
                "therapyName": "Nab-paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14794,
                    "pubMedId": null,
                    "title": "Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2\u2013Targeted Therapy",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.16.00037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing PIK3CA H1047R demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32307,
                "profileName": "NRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19580,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34236,
                "profileName": "PGR pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E726 and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by Piqray (Alpelisib) treatment compared to cells expressing individual PIK3CA mutations in culture, while cells expressing PIK3CA E726 and PIK3CA H1047R in trans did not (PMID: 31699932).",
            "molecularProfile": {
                "id": 34733,
                "profileName": "PIK3CA E726K PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E726K and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by GDC-0077 treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34733,
                "profileName": "PIK3CA E726K PIK3CA H1047R"
            },
            "therapy": {
                "id": 5181,
                "therapyName": "GDC-0077",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19949,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E726K and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34733,
                "profileName": "PIK3CA E726K PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19944,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E453Q and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by GDC-0077 treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34735,
                "profileName": "PIK3CA E453Q PIK3CA H1047R"
            },
            "therapy": {
                "id": 5181,
                "therapyName": "GDC-0077",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19940,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E543Q and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by Piqray (Alpelisib) treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34735,
                "profileName": "PIK3CA E453Q PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19948,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E453Q and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34735,
                "profileName": "PIK3CA E453Q PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20344,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of PIK3CA H1047R conferred resistance to Nerlynx (neratinib) in an ovarian cancer cell line harboring ERBB2 (HER2) G776V in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35133,
                "profileName": "ERBB2 G776V PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) to treatment with Nerlynx (neratinib) inhibited viability of an ovarian cancer cell line harboring ERBB2 (HER2) G776V and expressing PIK3CA H1047R in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35133,
                "profileName": "ERBB2 G776V PIK3CA H1047R"
            },
            "therapy": {
                "id": 5401,
                "therapyName": "Everolimus + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20340,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) resulted in a moderate delay of tumor growth in a breast cancer patient-derived xenograft model harboring ERBB2 (HER2) G778_P780dup and PIK3CA H1074R (PMID: 31978326).",
            "molecularProfile": {
                "id": 35134,
                "profileName": "ERBB2 G778_P780dup PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Nerlynx (neratinib) worked synergistically to inhibit viability of a breast cancer cell line harboring ERBB2 (HER2) V777L and PIK3CA H1047R in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35135,
                "profileName": "ERBB2 V777L PIK3CA H1047R"
            },
            "therapy": {
                "id": 5401,
                "therapyName": "Everolimus + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring ERBB2 (HER2) V777L and PIK3CA H1047R demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35135,
                "profileName": "ERBB2 V777L PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20341,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring ERBB2 (HER2) L755S and PIK3CA H1047R demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35136,
                "profileName": "ERBB2 L755S PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20387,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Nerlynx (neratinib) worked synergistically to inhibit viability of a breast cancer cell line harboring ERBB2 (HER2) L755S and PIK3CA H1047R in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35136,
                "profileName": "ERBB2 L755S PIK3CA H1047R"
            },
            "therapy": {
                "id": 5401,
                "therapyName": "Everolimus + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1575,
            "profileName": "ERBB2 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1731,
            "profileName": "PIK3CA H1047R",
            "profileTreatmentApproaches": [
                {
                    "id": 17060,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA H1047R"
                },
                {
                    "id": 17059,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA H1047R"
                },
                {
                    "id": 17062,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA H1047R"
                },
                {
                    "id": 17056,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA H1047R"
                },
                {
                    "id": 17058,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA H1047R"
                },
                {
                    "id": 17061,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA H1047R"
                },
                {
                    "id": 17055,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA H1047R"
                },
                {
                    "id": 17057,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA H1047R"
                }
            ]
        },
        {
            "id": 3606,
            "profileName": "MYC amp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9797,
            "profileName": "PIK3CA P539R PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10711,
            "profileName": "KRAS G13D PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10752,
            "profileName": "ERBB2 amp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18592,
            "profileName": "KRAS mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20269,
            "profileName": "ESR1 pos PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20308,
            "profileName": "PIK3CA K111R PIK3CA H1047R PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21303,
            "profileName": "KRAS wild-type PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24398,
            "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25513,
            "profileName": "ERBB2 over exp PIK3CA H1047R SRC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25951,
            "profileName": "ERBB2 pos PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26047,
            "profileName": "AKT3 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26168,
            "profileName": "PIK3CA H1047R PTCH1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26356,
            "profileName": "BRAF V600E PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26360,
            "profileName": "KRAS G13D PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26361,
            "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26366,
            "profileName": "KRAS G12C PIK3CA H1047R TP53 R248W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26370,
            "profileName": "MYC over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26372,
            "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26376,
            "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26449,
            "profileName": "PIK3CA H1047R PTEN E307K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26472,
            "profileName": "FGF3 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26475,
            "profileName": "GPR161 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26480,
            "profileName": "PIK3CA H1047R TBC1D3G over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26481,
            "profileName": "CCND1 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26484,
            "profileName": "PIK3CA H1047R SRP54 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26487,
            "profileName": "PIK3CA H1047R PLEKHF1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26490,
            "profileName": "CRB3 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26492,
            "profileName": "PIK3CA H1047R PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26496,
            "profileName": "AKT1 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26507,
            "profileName": "AKT2 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26511,
            "profileName": "PDPK1 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26514,
            "profileName": "PIK3CA H1047R SAMD4B over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26518,
            "profileName": "NUDT3 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26522,
            "profileName": "PIK3CA H1047R USP38 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26524,
            "profileName": "MFSD5 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26530,
            "profileName": "PIK3CA H1047R PIM1 over exp PTEN E307K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26535,
            "profileName": "PIK3CA H1047R PIM2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26536,
            "profileName": "PIK3CA H1047R PIM3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26539,
            "profileName": "PIK3CA P539R PIK3CA H1047R PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26623,
            "profileName": "MST1R pos PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26839,
            "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27242,
            "profileName": "PIK3CA H1047R PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27594,
            "profileName": "PIK3CA H1047R TP53 S90fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27820,
            "profileName": "KRAS G12F PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28117,
            "profileName": "ERBB3 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31777,
            "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32307,
            "profileName": "NRAS mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34236,
            "profileName": "PGR pos PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34733,
            "profileName": "PIK3CA E726K PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34735,
            "profileName": "PIK3CA E453Q PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35133,
            "profileName": "ERBB2 G776V PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35134,
            "profileName": "ERBB2 G778_P780dup PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35135,
            "profileName": "ERBB2 V777L PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35136,
            "profileName": "ERBB2 L755S PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35459,
            "profileName": "HRAS mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171860,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179234297A>G",
            "cDna": "c.3140A>G",
            "protein": "p.H1047R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171862,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179234297A>G",
            "cDna": "c.3140A>G",
            "protein": "p.H1047R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171861,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179234297A>G",
            "cDna": "c.3140A>G",
            "protein": "p.H1047R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}